Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Drug Efficacy and Maintenance - Lily's obesity pill shows potential as a maintenance treatment for weight loss, allowing patients to maintain weight loss without weekly injections [1] - Patients in the BGOI group regained approximately 2 pounds (约 0.9 千克) of their weight after one year [2] - Patients in the Zeppbound group regained approximately 11 pounds (约 5 千克) of their weight after one year [2] - The pill helps patients maintain the majority of weight initially lost through injections [1] Market Implications - The pill could play a significant role in the weight loss drug market as a maintenance treatment, potentially increasing drug uptake after approval [2] Pricing and Availability - The exact pricing for Novaortis or Eli Lilly's pills is currently unknown, as it is typically announced post-approval [3] - Initial doses for the pills may be priced at $150 per month for cash payments through the Trump RX direct-to-consumer website, launching in January 2026 [3] - The pricing for higher doses of the pills remains undisclosed [4]